PCRopsis™ Reagent RVD + PCRopsis™ RVD Enhancer offers a direct PCR solution for specimens in most non-inactivating transport mediums.

PCRopsis™ Reagent RVD alone has been repeatedly shown to facilitate extraction-free amplification of viral, bacterial, and mammalian specimens in universal viral transport (UVT) mediums, like BD™ Universal Viral Transport system. This is one of the most common specimen transport mediums in the U.S., although many other transport mediums are used in the U.S. and abroad.

Entopsis developed PCRopsis™ RVD Enhancer to expand the compatibility of PCRopsis™ Reagent RVD to process specimens in diverse transport mediums. PCRopsis™ Reagent RVD, when used in

Reagent RVD has proven capable of amplifying SARS-CoV-2 gene targets directly from universal viral transport (UVT) medium without the need for viral RNA extraction. However, diagnostic reference laboratories also want to use this approach for the amplification of bacterial gene targets.

The PCRopsis research team has extended their validation efforts in this direction. It’s been confirmed that Reagent RVD is capable of mediating extraction-free qPCR of specimens containing gram positive and negative bacteria.

To date, Reagent RVD facilitates extraction-free amplification of viral, bacterial and human gene targets directly from UVT.

This opens the door to new applications with Reagent

The U.S. National Academy of Medicine’s Healthy Longevity Global Grand Challenge has awarded a grant to develop Entopsis’ OpsisDx(TM) platform for detecting Parkinson’s disease using skin swabs or urine. This effort is driven by Entopsis’ scientific and clinical collaborators at Singapore’s Temasek Life Sciences Laboratory (TLL) and National Neuroscience Institute (NNI).

Read more about it here:

https://www.einnews.com/pr_news/529273833/national-academy-of-medicine-selects-opsisdx-for-co-development-of-a-urine-based-diagnostic-for-parkinson-s-disease

Non-invasive OpsisDx Diagnostic Test Awarded US Academy Research Grant

Our team’s passion is to innovate and create powerful, unheard-of solutions to the world’s problems. We pride ourselves on our creativity and desire to make a meaningful difference, both socially and scientifically.

However, we can only achieve our global goals with the right partners that share our mission. Today’s press release (see below) highlights one such partner, Madison Core Labs.

Link to Press Release

Madison Core Laboratories Initiates New Innovation Effort to Better Serve Clients

August 13, 2020 09:05 AM Eastern Daylight Time

HUNTSVILLE, Ala.–(BUSINESS WIRE)–Read more

Is viral RNA extraction necessary for amplifying genes from coronaviruses, like SARS-CoV-2?

NOT ANY MORE!

PCRopsis Reagent RVD allows you to perform direct RT-qPCR from nasopharyngeal / oropharyngeal samples transported in BD Universal Viral Transport media or Copan ESwab.

Simple Protocol:

  1. Mix sample 1:1 with Reagent RVD
  2. Heat to 95C for 10 minutes
  3. DONE… use ~5 uL into your RT-qPCR mix (can use 5 uL into a total 20 uL reaction)

Key Features:

  • Reagent RVD is an alternative to RNA extraction
  • Offers comparable RT-qPCR results to RNA extraction procedures for many applications in 10 MINUTES
  • Cost a fraction of traditional RNA extraction procedures, with fewer steps
  • Compatible with leading

1) CLIA Lab Director (Ph.D. with LDT development experience)
Location: Orlando, FL, USA

2) CLIA Medical Technologist (management experience needed)
Location: Orlando, FL, USA

3) Computer Scientist – Machine Learning
Location: Singapore, Singapore

4) Online Sales / Marketing
Location: global (all work is online)

5) Personal / Business Assistant to CEO (…a jack of all trades)
Location: Miami, FL, USA

6) Content Writer (little work experience necessary, but must be a daring writer)
Location: Miami, FL, USA

info@entopsis.com

Our team of multi-disciplinary scientists and engineers have once again improved on the NuTec Slide. This was only made possible by building on past insights and proprietary know-how. The latest version of NuTec Slides show improved reproducibility and sample discernment, while being able to handle a wider range of sample intensities. The Gen 5 NuTec Slide will be used for commercial applications in the U.S.

A shortage of COVID-19 testing supplies is hampering people’s ability to perform timely RT-PCR testing. A key bottleneck is viral RNA extraction, which involves multiple steps, reagents and devices.

Our team is now investigating whether we can apply our PCRopsis technology and know-how to facilitate direct RT-PCR from nasal-pharyngeal and saliva samples by skipping the RNA extraction step.

Stay tuned for research updates on this promising approach in the battle against the pandemic.

Check-out our other PCRopsis products that allow you to perform PCR directly from clinical samples: PCRopsis.com

Preliminary results are in from the on-going international clinical study exploring the ability of OpsisDx to accurately identify people with multiple diseases.

Highlights:

  1. OpsisDx distinguishes between people with cancer, hepatitis B viral and healthy controls
  2. OpsisDx accurately identifies patient’s cancer tissue of origin (lung, prostate, breast, liver or colorectal)
  3. Hepatitis B viral infection, often linked to increased likelihood for liver cancer, is observed as a distinct category from liver cancer patients
  4. OpsisDx detects more stage I cancers than liquid biopsies as performed by GRAIL

Can OpsisDx distinguish between similar molecules? Let’s say between different salts or isomers of carrageenan or phenol vs cresol?

YES … we observe distinct NuTec profiles for each molecule or mixture, even for molecules with similar structures.

This provides a framework for people to better grasp the inner workings of OpsisDx.